New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:07 EDTINSYTop prescriber of Insys drug probed for fraud, MLive says
Dr. Gavin Awerbuch, a neurologist that was paid $6.9M from 2009, through Feb. 6, 2014, for his prescriptions of Insys Therapeutics' cancer pain drug Subsys, was arraigned in federal court in Detroit on May 6 on charges of health care fraud, reported MLive yesterday. "Awerbuch is responsible for approximately 20.3% of the Subsys prescribed to Medicare beneficiaries nationwide during this time," the affidavit stated, according to the report. Shares of Insys were down more than 16% today. Reference Link
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
12:04 EDTINSYInsys Therapeutics cannabidiol receives FDA orphan designation
Subscribe for More Information
November 12, 2014
10:00 EDTINSYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:15 EDTINSYInsys Therapeutics downgraded at Oppenheimer
As noted earlier, Oppenheimer downgraded Insys to Perform from Outperform. The firm believes that the stock values Suybsys fairly at current levels, while the company's nearest-term pipeline opportunities will likely not materialize until 2016.
07:55 EDTINSYInsys Therapeutics downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
November 11, 2014
06:52 EDTINSYInsys Therapeutics reports Q3 non-GAAP EPS 63c, consensus 29c
Subscribe for More Information
November 10, 2014
15:26 EDTINSYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings DR Horton (DHI), consensus 48c; Sabre (SABR), consensus 26c; AECOM Technology (ACM), consensus 82c; CST Brands (CST), consensus 57c; Qiwi plc (QIWI), consensus 36c; INSYS Therapeutics (INSY), consensus 29c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use